Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: RMP who wrote (929)	1/19/1999 6:31:00 PM
From: Anthony Wong	Respond to of 2539

From a Bloomberg report on PFE earnings: Pfizer stepped up its marketing ahead of the introduction this year of a new potential blockbuster arthritis drug, Monsanto Co.'s Celebrex. Pfizer has agreed to market the drug with Monsanto. Celebrex could top annual sales of $1 billion because it appears to irritate the stomach less than other painkillers, such as aspirin. Celebrex could give Pfizer the third ''rookie of the year'' product, the best drug introduction for 1999 following similar success in 1997 and 1998, said Leonard Yaffe, an analyst with NationsBanc Montgomery Securities. news.com